{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:38:04Z","timestamp":1792431484353,"version":"4.5.0"},"reference-count":90,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100004763","name":"Inner Mongolia Natural Science Foundation","doi-asserted-by":"publisher","award":["2019MS08197"],"award-info":[{"award-number":["2019MS08197"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2021,3,10]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Drug resistance is the major cause of the failure of cancer chemotherapy, so one of the most\nimportant features in developing effective cancer therapeutic strategies is to overcome drug resistance.\nQuinoline moiety has become one of the most privileged structural motifs in anticancer agent discovery\nsince its derivatives possess potent activity against various cancers including drug-resistant cancers.\nSeveral quinoline-based compounds which are represented by Anlotinib, Bosutinib, Lenvatinib, and\nNeratinib have already been applied in clinical practice to fight against cancers, so quinoline-based\ncompounds are potential anticancer agents. The present short review article provides an overview of the\nrecent advances of quinoline-based compounds with potential activity against drug-resistant cancers.\nThe structure-activity relationship and mechanisms of action are also discussed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200618113957","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T15:50:37Z","timestamp":1592495437000},"page":"426-437","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Quinoline-based Compounds with Potential Activity against Drugresistant Cancers"],"prefix":"10.2174","volume":"21","author":[{"given":"Huan-Ting","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia, 014040,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhuji Affiliated Hospital of Shaoxing University, Zhejiang Province 311800,China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1021\/acs.jmedchem.7b01457","volume":"61","author":"Waghray D.","year":"2018","unstructured":"Waghray D.; Zhang Q.; Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J Med Chem 2018,61(12),5108-5121","journal-title":"J Med Chem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2017.04.006","volume":"115","author":"Mu L.M.","year":"2017","unstructured":"Mu L.M.; Ju R.J.; Liu R.; Bu Y.Z.; Zhang J.Y.; Li X.Q.; Zeng F.; Lu W.L.; Dual-functional drug liposomes in treatment of resistant cancers. Adv Drug Deliv Rev 2017,115,46-56","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2019.01.009","volume":"38","author":"Efferth T.","year":"2020","unstructured":"Efferth T.; Saeed M.E.M.; Kadioglu O.; Seo E.J.; Shirooie S.; Mbaveng A.T.; Nabavi S.M.; Kuete V.; Collateral sensitivity of natural products in drug-resistant cancer cells. Biotechnol Adv 2020,38","journal-title":"Biotechnol Adv"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100682","volume":"50","author":"Dallavalle S.","year":"2020","unstructured":"Dallavalle S.; Dobri&#x10D;i\u0107 V.; Lazzarato L.; Gazzano E.; Machuqueiro M.; Pajeva I.; Tsakovska I.; Zidar N.; Fruttero R.; Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist Updat 2020,50","journal-title":"Drug Resist Updat"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.drudis.2014.11.013","volume":"20","author":"Singh N.","year":"2015","unstructured":"Singh N.; Krishnakumar S.; Kanwar R.K.; Cheung C.H.; Kanwar J.R.; Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discov Today 2015,20(5),578-587","journal-title":"Drug Discov Today"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.12.012","author":"Onzalez-Fierro A.","year":"2020","unstructured":"Onzalez-Fierro A.; Due&#xF1;as-Gonz&#xE1;lez A.; Drug repurposing for cancer therapy, easier said than done. Semin Cancer Biol 2020","journal-title":"Semin Cancer Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0924-8579(03)00264-4","volume":"22","author":"Wainwright M.","year":"2003","unstructured":"Wainwright M.; Kristiansen J.E.; Quinoline and cyanine dyes--putative anti-MRSA drugs. Int J Antimicrob Agents 2003,22(5),479-486","journal-title":"Int J Antimicrob Agents"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ejmech.2018.08.061","volume":"157","author":"Gao C.","year":"2018","unstructured":"Gao C.; Fan Y.L.; Zhao F.; Ren Q.C.; Wu X.; Chang L.; Gao F.; Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA). Eur J Med Chem 2018,157,1081-1095","journal-title":"Eur J Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/med.21643","volume":"40","author":"Feng L.S.","year":"2020","unstructured":"Feng L.S.; Xu Z.; Chang L.; Li C.; Yan X.F.; Gao C.; Ding C.; Zhao F.; Shi F.; Wu X.; Hybrid molecules with potential in vitro antiplasmodial and in vivo antimalarial activity against drug-resistant Plasmodium falciparum. Med Res Rev 2020,40(3),931-971","journal-title":"Med Res Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejmech.2017.07.061","volume":"139","author":"Hu Y.Q.","year":"2017","unstructured":"Hu Y.Q.; Gao C.; Zhang S.; Xu L.; Xu Z.; Feng L.S.; Wu X.; Zhao F.; Quinoline hybrids and their antiplasmodial and antimalarial activities. Eur J Med Chem 2017,139,22-47","journal-title":"Eur J Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acs.jnatprod.5b00896","volume":"79","author":"Cretton S.","year":"2016","unstructured":"Cretton S.; Dorsaz S.; Azzollini A.; Favre-Godal Q.; Marcourt L.; Ebrahimi S.N.; Voinesco F.; Michellod E.; Sanglard D.; Gindro K.; Wolfender J.L.; Cuendet M.; Christen P.; Antifungal Quinoline Alkaloids from Waltheria indica. J Nat Prod 2016,79(2),300-307","journal-title":"J Nat Prod"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.2174\/092986710791163966","volume":"17","author":"Musiol R.","year":"2010","unstructured":"Musiol R.; Serda M.; Hensel-Bielowka S.; Polanski J.; Quinoline-based antifungals. Curr Med Chem 2010,17(18),1960-1973","journal-title":"Curr Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2174\/1389557518666181018163448","volume":"19","author":"Chokkar N.","year":"2019","unstructured":"Chokkar N.; Kalra S.; Chauhan M.; Kumar R.; A review on quinoline derived scaffolds as anti-HIV agents. Mini Rev Med Chem 2019,19(6),510-526","journal-title":"Mini Rev Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.2174\/1381612811319100008","volume":"19","author":"Musiol R.","year":"2013","unstructured":"Musiol R.; Quinoline-based HIV integrase inhibitors. Curr Pharm Des 2013,19(10),1835-1849","journal-title":"Curr Pharm Des"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.biopha.2014.10.007","volume":"68","author":"Keri R.S.","year":"2014","unstructured":"Keri R.S.; Patil S.A.; Quinoline: a promising antitubercular target. Biomed Pharmacother 2014,68(8),1161-1175","journal-title":"Biomed Pharmacother"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/1568026619666190304130218","volume":"19","author":"Das S.","year":"2019","unstructured":"Das S.; Garg T.; Srinivas N.; Dasgupta A.; Chopra S.; Targeting DNA Gyrase to combat Mycobacterium tuberculosis: An update. Curr Top Med Chem 2019,19(8),579-593","journal-title":"Curr Top Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2174\/1871520615666141216125446","volume":"15","author":"Gopaul K.","year":"2015","unstructured":"Gopaul K.; Shintre S.A.; Koorbanally N.A.; A review on the synthesis and anti-cancer activity of 2-substituted quinolines. Anticancer Agents Med Chem 2015,15(5),631-646","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=18","first-page":"10","volume":"12","author":"Aly R.M.","year":"2016","unstructured":"Aly R.M.; Serya R.A.T.; El-Motwally A.M.; Al-Ansary G.H.; Ella D.A.A.E.; Quinoline-based small molecules as effective protein kinases inhibitors. J Am Sci 2016,12(5),10-32","journal-title":"J Am Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1016\/j.arabjc.2016.10.009","volume":"12","author":"Jain S.","year":"2019","unstructured":"Jain S.; Chandra V.; Jain P.K.; Pathak K.; Pathak D.; Vaidya A.; Comprehensive review on current developments of quinoline-based anticancer agents. Arab J Chem 2019,12(8),4920-4946","journal-title":"Arab J Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.2174\/092986711795328382","volume":"18","author":"Solomon V.R.","year":"2011","unstructured":"Solomon V.R.; Lee H.; Quinoline as a privileged scaffold in cancer drug discovery. Curr Med Chem 2011,18(10),1488-1508","journal-title":"Curr Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"Han B.","year":"2018","unstructured":"Han B.; Li K.; Wang Q.; Zhang L.; Shi J.; Wang Z.; Cheng Y.; He J.; Shi Y.; Zhao Y.; Yu H.; Zhao Y.; Chen W.; Luo Y.; Wu L.; Wang X.; Pirker R.; Nan K.; Jin F.; Dong J.; Li B.; Sun Y.; Li, B.; Sun, Y. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer. The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol 2018,4(11),1569-1575","journal-title":"JAMA Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.achaem.2017.03.002","volume":"48","author":"Ochrem B.","year":"2017","unstructured":"Ochrem B.; Sacha T.; Efficacy and safety of bosutinib in the second and third line of treatment in chronic myeloid leukemia. Acta Haematol Pol 2017,48(4),274-281","journal-title":"Acta Haematol Pol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","volume":"42","author":"Cabanillas M.E.","year":"2016","unstructured":"Cabanillas M.E.; Habra M.A.; Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev 2016,42,47-55","journal-title":"Cancer Treat Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.clbc.2016.05.016","volume":"16","author":"Tiwari S.R.","year":"2016","unstructured":"Tiwari S.R.; Mishra P.; Abraham J.; Neratinib. A novel HER2-targeted tyrosine kinase inhibitor. Clin Breast Cancer 2016,16(5),344-348","journal-title":"Clin Breast Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ejmech.2016.08.039","volume":"124","year":"2016","unstructured":"Shaveta; Mishra, S.; Singh, P. Hybrid molecules: The privileged scaffolds for various pharmaceuticals. Eur J Med Chem 2016,124,500-536","journal-title":"Eur J Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1016\/j.bmc.2018.05.042","volume":"26","author":"Ibrar A.","year":"2018","unstructured":"Ibrar A.; Shehzadi S.A.; Saeed F.; Khan I.; Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery. Bioorg Med Chem 2018,26(13),3731-3762","journal-title":"Bioorg Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ejmech.2014.07.044","volume":"97","author":"Afzal O.","year":"2015","unstructured":"Afzal O.; Kumar S.; Haider M.R.; Ali M.R.; Kumar R.; Jaggi M.; Bawa S.; A review on anticancer potential of bioactive heterocycle quinoline. Eur J Med Chem 2015,97,871-910","journal-title":"Eur J Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejmech.2019.01.017","volume":"165","author":"Gao F.","year":"2019","unstructured":"Gao F.; Zhang X.; Wang T.; Xiao J.; Quinolone hybrids and their anti-cancer activities: An overview. Eur J Med Chem 2019,165,59-79","journal-title":"Eur J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010186","volume":"5","author":"Hawtin R.E.","year":"2010","unstructured":"Hawtin R.E.; Stockett D.E.; Byl J.A.W.; McDowell R.S.; Nguyen T.; Arkin M.R.; Conroy A.; Yang W.; Osheroff N.; Fox J.A.; Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One 2010,5(4)","journal-title":"PLoS One"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1158\/0008-5472.CAN-14-3370","volume":"75","author":"Pundir S.","year":"2015","unstructured":"Pundir S.; Vu H.Y.; Solomon V.R.; McClure R.; Lee H.; VR23: A quinoline-sulfonyl hybrid proteasome inhibitor that selectively kills cancer via cyclin E-mediated centrosome amplification. Cancer Res 2015,75(19),4164-4175","journal-title":"Cancer Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1021\/acs.jmedchem.8b00270","volume":"61","author":"Yang S.M.","year":"2018","unstructured":"Yang S.M.; Martinez N.J.; Yasgar A.; Danchik C.; Johansson C.; Wang Y.; Baljinnyam B.; Wang A.Q.; Xu X.; Shah P.; Cheff D.; Wang X.S.; Roth J.; Lal-Nag M.; Dunford J.E.; Oppermann U.; Vasiliou V.; Simeonov A.; Jadhav A.; Maloney D.J.; Maloney D.J.; Discovery of orally bioavailable, quinoline-based aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with potent cellular activity. J Med Chem 2018,61(11),4883-4903","journal-title":"J Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"27772","DOI":"10.18632\/oncotarget.15115","volume":"8","author":"Chao M.W.","year":"2017","unstructured":"Chao M.W.; Huang H.L.; HuangFu, W.C.; Hsu, K.C.; Liu, Y.M.; Wu, Y.W.; Lin, C.F.; Chen, Y.L.; Lai, M.J.; Lee, H.Y.; Liou, J.P.; Teng, C.M.; Yang, C.R. An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells. Oncotarget 2017,8(17),27772-27785","journal-title":"Oncotarget"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1021\/acs.jmedchem.8b01386","volume":"62","author":"Naret T.","year":"2019","unstructured":"Naret T.; Khelifi I.; Provot O.; Bignon J.; Levaique H.; Dubois J.; Souce M.; Kasselouri A.; Deroussent A.; Paci A.; Varela P.F.; Gigant B.; Alami M.; Hamze A.; 1,1-Diheterocyclic ethylenes derived from quinaldine and carbazole as new tubulin polymerization inhibitors: Synthesis, metabolism, and biological evaluation. J Med Chem 2019,62(4),1902-1916","journal-title":"J Med Chem"},{"key":"ref=34","first-page":"1245","volume":"38","author":"Ashizawa T.","year":"2011","unstructured":"Ashizawa T.; Miyata H.; Ishii H.; Oshita C.; Matsuno K.; Masuda Y.; Furuya T.; Okawara T.; Otsuka M.; Ogo N.; Asai A.; Akiyama Y.; Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol 2011,38(5),1245-1252","journal-title":"Int J Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3892\/ijo.2013.1916","volume":"43","author":"Ashizawa T.","year":"2013","unstructured":"Ashizawa T.; Miyata H.; Iizuka A.; Komiyama M.; Oshita C.; Kume A.; Nogami M.; Yagoto M.; Ito I.; Oishi T.; Watanabe R.; Mitsuya K.; Matsuno K.; Furuya T.; Okawara T.; Otsuka M.; Ogo N.; Asai A.; Nakasu Y.; Yamaguchi K.; Akiyama Y.; Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol 2013,43(1),219-227","journal-title":"Int J Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3892\/ijo.2014.2439","volume":"45","author":"Ashizawa T.","year":"2014","unstructured":"Ashizawa T.; Akiyama Y.; Miyata H.; Iizuka A.; Komiyama M.; Kume A.; Omiya M.; Sugino T.; Asai A.; Hayashi N.; Mitsuya K.; Nakasu Y.; Yamaguchi K.; Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line. Int J Oncol 2014,45(1),411-418","journal-title":"Int J Oncol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"9205","DOI":"10.1021\/acs.jmedchem.7b01039","volume":"60","author":"Mah S.","year":"2017","unstructured":"Mah S.; Park J.H.; Jung H.Y.; Ahn K.; Choi S.; Tae H.S.; Jung K.H.; Rho J.K.; Lee J.C.; Hong S.S.; Hong S.; Identification of 4-phenoxyquinoline based inhibitors for L1196M mutant of anaplastic lymphoma kinase by structure-based design. J Med Chem 2017,60(22),9205-9221","journal-title":"J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nchembio.2326","volume":"13","author":"Li J.","year":"2017","unstructured":"Li J.; Yakushi T.; Parlati F.; Mackinnon A.L.; Perez C.; Ma Y.; Carter K.P.; Colayco S.; Magnuson G.; Brown B.; Nguyen K.; Vasile S.; Suyama E.; Smith L.H.; Sergienko E.; Pinkerton A.B.; Chung T.D.Y.; Palmer A.E.; Pass I.; Hess S.; Cohen S.M.; Deshaies R.J.; Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nat Chem Biol 2017,13(5),486-493","journal-title":"Nat Chem Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1248\/cpb.c18-00308","volume":"66","author":"Arai M.A.","year":"2018","unstructured":"Arai M.A.; Masuda A.; Suganami A.; Tamura Y.; Ishibashi M.; Synthesis and evaluation of fuligocandin B derivatives with activity for overcoming TRAIL resistance. Chem Pharm Bull (Tokyo) 2018,66(8),810-817","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neo.2017.11.006","volume":"20","author":"Chen T.L.","year":"2018","unstructured":"Chen T.L.; Lin Y.W.; Chen Y.B.; Lin J.J.; Su T.L.; Shen C.N.; Lee T.C.; A low-toxicity DNA-alkylating N-mustard-quinoline conjugate with preferential sequence specificity exerts potent antitumor activity against colorectal cancer. Neoplasia 2018,20(2),119-130","journal-title":"Neoplasia"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1016\/j.bmcl.2014.04.091","volume":"24","author":"Chen M.","year":"2014","unstructured":"Chen M.; Chen H.; Ma J.; Liu X.; Zhang S.; Synthesis and anticancer activity of novel quinoline-docetaxel analogues. Bioorg Med Chem Lett 2014,24(13),2867-2870","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=42","first-page":"3457","volume":"34","author":"Park H.S.","year":"2014","unstructured":"Park H.S.; Hong S.K.; Oh M.M.; Yoon C.Y.; Jeong S.J.; Byun S.S.; Cheon J.; Lee S.E.; Moon G.; Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. Anticancer Res 2014,34(7),3457-3468","journal-title":"Anticancer Res"},{"key":"ref=43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020899","volume":"6","author":"Xu C.X.","year":"2011","unstructured":"Xu C.X.; Li Y.; Yue P.; Owonikoko T.K.; Ramalingam S.S.; Khuri F.R.; Sun S.Y.; The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One 2011,6(6)","journal-title":"PLoS One"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.juro.2013.07.101","volume":"191","author":"Yasumizu Y.","year":"2014","unstructured":"Yasumizu Y.; Miyajima A.; Kosaka T.; Miyazaki Y.; Kikuchi E.; Oya M.; Dual PI3K\/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J Urol 2014,191(1),227-234","journal-title":"J Urol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"8097","DOI":"10.1158\/0008-5472.CAN-10-1814","volume":"70","author":"Chiarini F.","year":"2010","unstructured":"Chiarini F.; Grimaldi C.; Ricci F.; Tazzari P.L.; Evangelisti C.; Ognibene A.; Battistelli M.; Falcieri E.; Melchionda F.; Pession A.; Pagliaro P.; McCubrey J.A.; Martelli A.M.; Activity of the novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010,70(20),8097-8107","journal-title":"Cancer Res"},{"key":"ref=46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037431","volume":"7","author":"Shoji K.","year":"2012","unstructured":"Shoji K.; Oda K.; Kashiyama T.; Ikeda Y.; Nakagawa S.; Sone K.; Miyamoto Y.; Hiraike H.; Tanikawa M.; Miyasaka A.; Koso T.; Matsumoto Y.; Wada-Hiraike O.; Kawana K.; Kuramoto H.; McCormick F.; Aburatani H.; Yano T.; Kozuma S.; Taketani Y.; Genotype-dependent efficacy of a dual PI3K\/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One 2012,7(5)","journal-title":"PLoS One"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3892\/ijo.2014.2505","volume":"45","author":"Moon G.","year":"2014","unstructured":"Moon G.; Lee S.E.; Oh M.M.; Lee S.C.; Jeong S.J.; Hong S.K.; Yoon C.Y.; Byun S.S.; Park H.S.; Cheon J.; NVP-BEZ235, a dual PI3K\/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol 2014,45(3),1027-1035","journal-title":"Int J Oncol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bmc.2014.11.043","volume":"23","author":"Karthikeyan C.","year":"2015","unstructured":"Karthikeyan C.; Lee C.; Moore J.; Mittal R.; Suswam E.A.; Abbott K.L.; Pondugula S.R.; Manne U.; Narayanan N.K.; Trivedi P.; Towari A.K.; IND-2, a pyrimido[1&#x201D;,2&#x201D;:1,5] pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells. Bioorg Med Chem 2015,23(3),602-611","journal-title":"Bioorg Med Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.canlet.2016.03.030","volume":"376","author":"Karthikeyan C.","year":"2016","unstructured":"Karthikeyan C.; Malla R.; Ashby C.R.; Amawi H.; Abbott K.L.; Moore J.; Chen J.; Balch C.; Lee C.; Flannery P.C.; Trivedi P.; Faridi J.S.; Pondugula S.R.; Tiwari A.K.; Pyrimido[1\u2033,2\u2033:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells. Cancer Lett 2016,376(1),118-126","journal-title":"Cancer Lett"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","volume":"70","author":"Siddiqui-Jain A.","year":"2010","unstructured":"Siddiqui-Jain A.; Drygin D.; Streiner N.; Chua P.; Pierre F.; O\u2019Brien S.E.; Bliesath J.; Omori M.; Huser N.; Ho C.; Proffitt C.; Schwaebe M.K.; Ryckman D.M.; Rice W.G.; Anderes K.; CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010,70(24),10288-10298","journal-title":"Cancer Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1021\/jm101251q","volume":"54","author":"Pierre F.","year":"2011","unstructured":"Pierre F.; Chua P.C.; O\u2019Brien S.E.; Siddiqui-Jain A.; Bourbon P.; Haddach M.; Michaux J.; Nagasawa J.; Schwaebe M.K.; Stefan E.; Vialettes A.; Whitten J.P.; Chen T.K.; Darjania L.; Stansfield R.; Anderes K.; Bliesath J.; Drygin D.; Ho C.; Omori M.; Proffitt C.; Streiner N.; Trent K.; Rice W.G.; Ryckman D.M.; Discovery and SAR of 5-(3-chlorophenylamino)benzo[c] [2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem 2011,54(2),635-654","journal-title":"J Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/1535-7163.MCT-11-0613","volume":"11","author":"Siddiqui-Jain A.","year":"2012","unstructured":"Siddiqui-Jain A.; Bliesath J.; Macalino D.; Omori M.; Huser N.; Streiner N.; Ho C.B.; Anderes K.; Proffitt C.; O\u2019Brien S.E.; Lim J.K.; Von Hoff D.D.; Ryckman D.M.; Rice W.G.; Drygin D.; CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther 2012,11(4),994-1005","journal-title":"Mol Cancer Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2012.02.032","volume":"322","author":"Bliesath J.","year":"2012","unstructured":"Bliesath J.; Huser N.; Omori M.; Bunag D.; Proffitt C.; Streiner N.; Ho C.; Siddiqui-Jain A.; O\u2019Brien S.E.; Lim J.K.; Ryckman D.M.; Anderes K.; Rice W.G.; Drygin D.; Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett 2012,322(1),113-118","journal-title":"Cancer Lett"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049193","volume":"7","author":"Zanin S.","year":"2012","unstructured":"Zanin S.; Borgo C.; Girardi C.; O\u2019Brien S.E.; Miyata Y.; Pinna L.A.; Donella-Deana A.; Ruzzene M.; Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells. PLoS One 2012,7(11)","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1248\/bpb.25.1385","volume":"25","author":"Shimizu K.","year":"2002","unstructured":"Shimizu K.; Takada M.; Asai T.; Kuromi K.; Baba K.; Oku N.; Cancer chemotherapy by liposomal 6-[12-(dimethylamino)ethyl]aminol-3-hydroxy-7H-indeno[2,1-clquinolin-7-one dihydrochloride (TAS-103), a novel anti-cancer agent. Biol Pharm Bull 2002,25(10),1385-1387","journal-title":"Biol Pharm Bull"},{"key":"ref=56","first-page":"219","volume":"11","author":"Parajuli P.","year":"1999","unstructured":"Parajuli P.; Yano S.; Nishioka Y.; Nokihara H.; Hanibuchi M.; Nishimura N.; Utsugi T.; Sone S.; Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer. Oncol Res 1999,11(5),219-224","journal-title":"Oncol Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1021\/jm800017u","volume":"51","author":"Ryckebusch A.","year":"2008","unstructured":"Ryckebusch A.; Garcin D.; Lansiaux A.; Goossens J.F.; Baldeyrou B.; Houssin R.; Bailly C.; H&#xE9;nichart J.P.; Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives. J Med Chem 2008,51(12),3617-3629","journal-title":"J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1021\/jm049387x","volume":"48","author":"Ferlin M.G.","year":"2005","unstructured":"Ferlin M.G.; Chiarelotto G.; Gasparotto V.; Dalla Via L.; Pezzi V.; Barzon L.; Pal&#xF9; G.; Castagliuolo I.; Synthesis and in vitro and in vivo antitumor activity of 2-phenylpyrroloquinolin-4-ones. J Med Chem 2005,48(9),3417-3427","journal-title":"J Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1021\/jm0510676","volume":"49","author":"Gasparotto V.","year":"2006","unstructured":"Gasparotto V.; Castagliuolo I.; Chiarelotto G.; Pezzi V.; Montanaro D.; Brun P.; Pal&#xF9; G.; Viola G.; Ferlin M.G.; Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity. J Med Chem 2006,49(6),1910-1915","journal-title":"J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1021\/jm070534b","volume":"50","author":"Gasparotto V.","year":"2007","unstructured":"Gasparotto V.; Castagliuolo I.; Ferlin M.G.; 3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines. J Med Chem 2007,50(22),5509-5513","journal-title":"J Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.fitote.2019.01.003","volume":"133","author":"Nganou B.K.","year":"2019","unstructured":"Nganou B.K.; Mbaveng A.T.; Fobofou S.A.T.; Fankam A.G.; Bitchagno G.T.M.; Simo Mpetga J.D.; Wessjohann L.A.; Kuete V.; Efferth T.; Tane P.; Furoquinolines and dihydrooxazole alkaloids with cytotoxic activity from the stem bark of Araliopsis soyauxii. Fitoterapia 2019,133,193-199","journal-title":"Fitoterapia"},{"key":"ref=62","first-page":"683","volume":"73","author":"Badowska-Ros\u0142onek K.","year":"2016","unstructured":"Badowska-Ros\u0142onek K.; Ciesielska A.; Switalska M.; Piskozub M.; Peczy\u0144ska-Czoch W.; Wietrzyk J.; Kaczmarek \u0141.; Synthesis and cytotoxic activity of new 5H-indol[2,3-b]quinoline O-aminoglycosides. Acta Pol. Pharm.-. Acta Pol Pharm 2016,73(3),683-692","journal-title":"Acta Pol Pharm"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1016\/j.bmcl.2014.07.072","volume":"24","author":"Oyewumi M.O.","year":"2014","unstructured":"Oyewumi M.O.; Alazizi A.; Liva S.; Lin L.; Geldenhuys W.J.; Screening and identification of novel compounds with potential anti-proliferative effects on gallium-resistant lung cancer through an AXL kinase pathway. Bioorg Med Chem Lett 2014,24(18),4553-4556","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ejmech.2015.06.049","volume":"101","author":"Li X.Q.","year":"2015","unstructured":"Li X.Q.; Wang L.; Lei Y.; Hu T.; Zhang F.L.; Cho C.H.; To K.K.W.; Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. Eur J Med Chem 2015,101,560-572","journal-title":"Eur J Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.taap.2018.10.025","volume":"362","author":"Ranjbar S.","year":"2019","unstructured":"Ranjbar S.; Khonkarn R.; Moreno A.; Baubichon-Cortay H.; Miri R.; Khoshneviszadeh M.; Saso L.; Edraki N.; Falson P.; Firuzi O.; 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells. Toxicol Appl Pharmacol 2019,362,136-149","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2019.06.001","author":"Ong Y.C.","year":"2020","unstructured":"Ong Y.C.; Gasser G.; Organometallic compounds in drug discovery: Past, present and future. Drug Discov Today Technol 2020","journal-title":"Drug Discov Today Technol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2174\/1871520614666140829124925","volume":"14","author":"Martins P.","year":"2014","unstructured":"Martins P.; Marques M.; Coito L.; Pombeiro A.J.L.; Baptista P.V.; Fernandes A.R.; Organometallic compounds in cancer therapy: Past lessons and future directions. Anticancer Agents Med Chem 2014,14(9),1199-1212","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112109","volume":"190","author":"Wang R.","year":"2020","unstructured":"Wang R.; Chen H.; Yan W.; Zheng M.; Zhang T.; Zhang Y.; Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships. Eur J Med Chem 2020,190","journal-title":"Eur J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cbpa.2014.02.003","volume":"19","author":"Muhammad N.","year":"2014","unstructured":"Muhammad N.; Guo Z.; Metal-based anticancer chemotherapeutic agents. Curr Opin Chem Biol 2014,19,144-153","journal-title":"Curr Opin Chem Biol"},{"key":"ref=70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"Ghosh S.","year":"2019","unstructured":"Ghosh S.; Cisplatin: The first metal based anticancer drug. Bioorg Chem 2019,88","journal-title":"Bioorg Chem"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1016\/j.poly.2020.114369","volume":"179","author":"Li S.","year":"2020","unstructured":"Li S.; Zhao J.; Yuan B.; Wang X.; Zhang J.; Yue L.; Hou H.; Hu J.; Chen S.; Crystal structure, DNA interaction and in vitro anticancer activity of Cu(II) and Pt(II) compounds based on benzimidazole-quinoline derivative. Polyhedron 2020,179","journal-title":"Polyhedron"},{"key":"ref=72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.07.042","volume":"27","author":"Othman D.I.A.","year":"2019","unstructured":"Othman D.I.A.; Selim K.B.; El-Sayed M.A.A.; Tantawy A.S.; Amen Y.; Shimizu K.; Okauchi T.; Kitamura M.; Design, synthesis and anticancer evaluation of new substituted thiophene-quinoline derivatives. Bioorg Med Chem 2019,27(19)","journal-title":"Bioorg Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ica.2018.06.003","volume":"482","author":"Thirunavukkarasu T.","year":"2018","unstructured":"Thirunavukkarasu T.; Spark H.A.; Natarajan K.; Quinoline based Pd(II) complexes: Synthesis, characterization and evaluation of DNA\/protein binding, molecular docking and in vitro anticancer activity. Inorg Chim Acta 2018,482,229-239","journal-title":"Inorg Chim Acta"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jinorgbio.2018.11.017","volume":"191","author":"Cao W.","year":"2019","unstructured":"Cao W.; Qi J.; Qian K.; Tian L.; Cheng Z.; Wang Y.; Structure-activity relationships of 2 quinolinecarboxaldehyde thiosemicarbazone gallium(III) complexes with potent and selective anticancer activity. J Inorg Biochem 2019,191,174-182","journal-title":"J Inorg Biochem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00280-019-03773-x","volume":"83","author":"Ruiz M.C.","year":"2019","unstructured":"Ruiz M.C.; Resasco A.; Di Virgilio A.L.; Ayala M.; Cavaco I.; Cabrera S.; Aleman J.; Le&#xF3;n I.E.; In vitro and in vivo anticancer effects of two quinoline-platinum(II) complexes on human osteosarcoma models. Cancer Chemother Pharmacol 2019,83(4),681-692","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111751","volume":"184","author":"Qin Q.P.","year":"2019","unstructured":"Qin Q.P.; Wang Z.F.; Huang X.L.; Tan M.X.; Zou B.Q.; Liang H.; Strong in vitro and vivo cytotoxicity of novel organoplatinum(II) complexes with quinoline-coumarin derivatives. Eur J Med Chem 2019,184","journal-title":"Eur J Med Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ejmech.2018.06.018","volume":"155","author":"Wang F.Y.","year":"2018","unstructured":"Wang F.Y.; Tang X.M.; Wang X.; Huang K.B.; Feng H.W.; Chen Z.F.; Liu Y.N.; Liang H.; Mitochondria-targeted platinum(II) complexes induce apoptosis-dependent autophagic cell death mediated by ER-stress in A549 cancer cells. Eur J Med Chem 2018,155,639-650","journal-title":"Eur J Med Chem"},{"key":"ref=78","first-page":"2809","volume":"36","author":"Arzuman L.","year":"2016","unstructured":"Arzuman L.; Beale P.; Yu J.Q.; Huq F.; Synthesis of tris(quinoline)monochloroplatinum(II) chloride and its activity alone and in combination with capsaicin and curcumin in human ovarian cancer cell lines. Anticancer Res 2016,36(6),2809-2818","journal-title":"Anticancer Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jinorgbio.2017.06.004","volume":"174","author":"Casado-S&#xE1;nchez A.","year":"2017","unstructured":"Casado-S&#xE1;nchez A.; Mart&#xED;n-Santos C.; Padr&#xF3;n J.M.; Mas-Ballest&#xE9; R.; Navarro-Ranninger C.; Alem&#xE1;n J.; Cabrera S.; Effect of electronic and steric properties of 8-substituted quinolines in gold(III) complexes: Synthesis, electrochemistry, stability, interactions and antiproliferative studies. J Inorg Biochem 2017,174,111-118","journal-title":"J Inorg Biochem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1039\/C3MT00341H","volume":"6","author":"Novohradsky V.","year":"2014","unstructured":"Novohradsky V.; Liu Z.; Vojtiskova M.; Sadler P.J.; Brabec V.; Kasparkova J.; Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand. Metallomics 2014,6(3),682-690","journal-title":"Metallomics"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bph.12427","volume":"171","author":"Tsai A.C.","year":"2014","unstructured":"Tsai A.C.; Pai H.C.; Wang C.Y.; Liou J.P.; Teng C.M.; Wang J.C.; Pan S.L.; In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells. Br J Pharmacol 2014,171(1),122-133","journal-title":"Br J Pharmacol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.biopha.2011.04.024","volume":"65","author":"Ganguly A.","year":"2011","unstructured":"Ganguly A.; Banerjee K.; Chakraborty P.; Das S.; Sarkar A.; Hazra A.; Banerjee M.; Maity A.; Chatterjee M.; Mondal N.B.; Choudhuri S.K.; Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative. Biomed Pharmacother 2011,65(6),387-394","journal-title":"Biomed Pharmacother"},{"key":"ref=83","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201800281","volume":"352","author":"Romero A.H.","year":"2019","unstructured":"Romero A.H.; Lopez S.E.; Arvelo F.; Sojo F.; Calderon C.; Morales. Identification of dehydroxy isoquine and isotebuquine as promising anticancer agents targeting K+ channel. Arch Pharm 2019,352(3)","journal-title":"Arch Pharm"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1158\/0008-5472.CAN-12-0743","volume":"72","author":"Caceres G.","year":"2012","unstructured":"Caceres G.; Robey R.W.; Sokol L.; McGraw K.L.; Clark J.; Lawrence N.J.; Sebti S.M.; Wiese M.; List A.F.; HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Res 2012,72(16),4204-4213","journal-title":"Cancer Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejmech.2016.02.069","volume":"114","author":"Shobeiri N.","year":"2016","unstructured":"Shobeiri N.; Rashedi M.; Mosaffa F.; Zarghi A.; Ghandadi M.; Ghasemi A.; Ghodsi R.; Synthesis and biological evaluation of quinoline analogues of flavones as potential anticancer agents and tubulin polymerization inhibitors. Eur J Med Chem 2016,114,14-23","journal-title":"Eur J Med Chem"},{"key":"ref=86","first-page":"9","volume":"21","author":"Aboutorabzadeh S.M.","year":"2018","unstructured":"Aboutorabzadeh S.M.; Mosaffa F.; Hadizadeh F.; Ghodsi R.; Design, synthesis, and biological evaluation of 6-methoxy-2-arylquinolines as potential P-glycoprotein inhibitors. Iran J Basic Med Sci 2018,21(1),9-18","journal-title":"Iran J Basic Med Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1021\/jm900685y","volume":"53","author":"Nien C.Y.","year":"2010","unstructured":"Nien C.Y.; Chen Y.C.; Kuo C.C.; Hsieh H.P.; Chang C.Y.; Wu J.S.; Wu S.Y.; Liou J.P.; Chang J.Y.; 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J Med Chem 2010,53(5),2309-2313","journal-title":"J Med Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.3390\/molecules16032274","volume":"16","author":"Hsieh C.C.","year":"2011","unstructured":"Hsieh C.C.; Lee H.Y.; Nien C.Y.; Kuo C.C.; Chang C.Y.; Chang J.Y.; Liou J.P.; Synthesis and biological evaluation of 4-aroyl-6,7,8-trimethoxyquinolines as a novel class of anticancer agents. Molecules 2011,16(3),2274-2284","journal-title":"Molecules"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.3390\/biology8040075","volume":"8","author":"Zhou Y.","year":"2019","unstructured":"Zhou Y.; Chung P.Y.; Ma J.Y.W.; Lam A.K.Y.; Law S.; Chan K.W.; Chan A.S.C.; Li X.; Lam K.H.; Chui C.H.; Tang J.C.; Development of a novel quinoline derivative as a P-glycoprotein inhibitor to reverse multidrug resistance in cancer cells. Biology (Basel) 2019,8(4)","journal-title":"Biology (Basel)"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejmech.2018.05.025","volume":"154","author":"Ling Y.","year":"2018","unstructured":"Ling Y.; Yang Q.X.; Teng Y.N.; Chen S.; Gao W.J.; Guo J.; Hsu P.L.; Liu Y.; Morris-Natschke S.L.; Hung C.C.; Lee K.H.; Development of novel amino-quinoline-5,8-dione derivatives as NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities. Eur J Med Chem 2018,154,199-209","journal-title":"Eur J Med Chem"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/182901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.eurekaselect.com\/182901\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/eurekaselect.com\/article\/download\/182901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,2]],"date-time":"2022-01-02T14:39:31Z","timestamp":1641134371000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/182901\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,3,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200618113957","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}